Compare IDEXX Laboratories, Inc. (IDXX) vs Nebius Group NV (NBIS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs Nebius Group NV — how do they compare? IDEXX Laboratories, Inc. trades at $546.1 (market cap $43.58B), while Nebius Group NV trades at $223.75 (market cap $55.08B). The key difference: Nebius Group NV is the larger of the two by market cap, and Nebius Group NV is trading nearer its 52-week high, IDEXX Laboratories, Inc. nearer its low. Which is the better fit depends on your goals.
| IDXX | NBIS | |
|---|---|---|
Market Cap | $43.58B | $55.08B |
Sector | Health | Technology |
52-Week High | $766.68 | $286.69 |
52-Week Low | $526.44 | $50.40 |
Enterprise Value | $44.48B | $55.27B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories trades at $552.46, down 2.64% today, with neutral technical signals but strong fundamental performance. The company maintains robust profitability with 24.63% net margins and has beaten earnings expectations for three consecutive quarters. Recent news highlights AI integration in medical devices and upcoming Q2 2026 results on August 4, 2026. The stock shows consistent revenue growth from $3.4B in 2022 to $4.3B in 2025.
Outlook remains positive given earnings momentum and analyst consensus, though elevated valuation ratios (P/E 41.49) pose risks. Key catalysts include Q2 earnings release and continued AI adoption in veterinary diagnostics. Primary risks involve competitive pressures and market volatility affecting premium valuations.
NBIS trades at $182.62, up 2.76% today, with a bearish technical signal despite oversold RSI readings. The company reported a net income of $82.50M in 2025, with revenue of $529.80M, and shows strong projected profit margin expansion to 93.08% in 2026. Recent news highlights a significant stake increase by Nvidia, fueling positive sentiment.
Outlook is mixed: strong analyst support (88.89% buy ratings) and a $260.67 price target suggest upside, but high valuation ratios (P/E 70.51) and negative cash flow from investing pose risks. Investor focus is on execution of AI-driven growth amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About Nebius Group NV
Nebius Group N.V. is a technology company specializing in AI, machine learning, and cloud computing solutions. The company provides a range of enterprise-level cloud services, including large-scale data processing, advanced analytics, and AI model development and deployment. Nebius Group focuses on serving businesses that require high-performance, scalable, and secure infrastructure to handle complex computational tasks and accelerate their digital transformation.
Read more on NBIS →
